Tenia Solium Infection
Conditions
Keywords
Taenia solium, neurocysticercosis, oxfendazole, clinical trial, phase 1, safety, pharmacokinetics
Brief summary
This research is being done to learn about the safety in humans of a medicine that is already used in cows and pigs to treat worms. The medicine may be useful for people who have these or other worms. The medicine will be studied first in healthy people, who will be given a very small amount of the medicine once. If the smallest amount of medicine is found to be safe, a slightly higher amount will be given to a new group of volunteers. The highest amount that will be tested is similar to the amount given to animals. If the medicine can be given safely to healthy people in the planned amounts, a later study will be done in people who have worms to see if the medicine kills the worms.
Detailed description
The Phase I study proposed is a randomized, double-blind, placebo-controlled evaluation of the safety and pharmacokinetics of escalating single oral doses of oxfendazole (0.3 to 30 mg/kg) in healthy volunteers. The dose will be increased approximately three-fold (one-half log) at each increment, and each cohort will comprise ten volunteers (eight drug, two placebo). Subjects will be monitored for three weeks after dosing, including monitoring the pharmacokinetics and metabolism of oxfendazole in blood and urine. Each new cohort will be dosed only after the three week safety data for the preceding group have been analyzed. If a clinically significant adverse event is observed, and if this event is possibly drug-related, an additional (and final) cohort of volunteers will repeat the highest tolerated dose of oxfendazole. Up to 70 volunteers (56 drug, 14 placebo) will complete the study.
Interventions
DRUGoxfendazole
administration of a single oral 1.0 mg/kg dose of oxfendazole
DRUGplacebo
single oral dose of placebo
Sponsors
Universidad Peruana Cayetano Heredia
School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos
Johns Hopkins Bloomberg School of Public Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Height and weight within 25% of means for his/her gender and age. * Willing to use two acceptable methods of contraception (approved oral, injectable, or implantable drug, IUD, diaphragm or condom with spermicidal jelly or foam, or sexual abstinence) for a minimum of one week before, and three weeks after dosing with oxfendazole; or surgically sterile. * Able to give written informed consent. * Able to provide a home phone number, and the name, address, and phone number of a person willing to assist making contact during the follow-up phase of the study.
Exclusion criteria
* Pregnant. * Breast feeding. * Chronic drug/alcohol user. * Has clinically significant abnormalities in screening examinations * Has history of sensitivity to related benzimidazole compounds (e.g. albendazole, mebendazole).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serious adverse events | up to three weeks after dosing | Proportion of patients who present with serious adverse events (SAEs) related to oxfendazole. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| adverse events | up to three weeks after dosing | proportion of subjects who present with adverse events (AEs) related to ocfendazole |
| Pharmacokinetic Profile | blood samples are drawn at 17 time points up to three weeks and urine is collected at 7 intervals up to 72 hours after dosing | The following PK parameters will be analyzed: Maximum plasma concentration (Cmax), Time to Cmax (Tmax), Elimination rate constant (Iz), Elimination half-life (T½), Area under the curve to the final sample (AUC0-t), Area under the curve to infinity (AUC∞), Oral clearance (CL/F), Oral volume of distribution (Vz/F) |
Outcome results
None listed